tradingkey.logo

Nexalin Technology Inc

NXL
0.832USD
+0.026+3.29%
收盘 12/19, 16:00美东报价延迟15分钟
15.13M总市值
亏损市盈率 TTM

Nexalin Technology Inc

0.832
+0.026+3.29%

关于 Nexalin Technology Inc 公司

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Inc简介

公司代码NXL
公司名称Nexalin Technology Inc
上市日期Sep 16, 2022
CEOWhite (Mark)
员工数量6
证券类型Ordinary Share
年结日Sep 16
公司地址1776 Yorktown
城市HOUSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编77056
电话18322600222
网址https://nexalin.com
公司代码NXL
上市日期Sep 16, 2022
CEOWhite (Mark)

Nexalin Technology Inc公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
185.75K
+24.42%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+25.00%
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
185.75K
+24.42%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+25.00%

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Equipment
52.53K
74.41%
Licensing Fee
10.36K
14.67%
Other
7.71K
10.92%
地区USD
名称
营收
占比
International Sales
59.48K
84.26%
U.S. Sales
11.11K
15.74%
业务
地区
业务USD
名称
营收
占比
Equipment
52.53K
74.41%
Licensing Fee
10.36K
14.67%
Other
7.71K
10.92%

股东统计

更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Elson (Marilyn)
8.23%
Hu (Benjamin)
2.02%
White (Mark)
1.66%
Owens (David)
1.00%
The Vanguard Group, Inc.
0.95%
其他
86.15%
持股股东
持股股东
占比
Elson (Marilyn)
8.23%
Hu (Benjamin)
2.02%
White (Mark)
1.66%
Owens (David)
1.00%
The Vanguard Group, Inc.
0.95%
其他
86.15%
股东类型
持股股东
占比
Individual Investor
13.78%
Investment Advisor
1.50%
Hedge Fund
1.11%
Investment Advisor/Hedge Fund
0.96%
Research Firm
0.16%
Venture Capital
0.06%
其他
82.44%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
37
1.33M
7.29%
+710.60K
2025Q2
41
2.88M
16.54%
-349.86K
2025Q1
40
2.89M
20.99%
-330.73K
2024Q4
39
2.84M
22.05%
+425.03K
2024Q3
30
2.89M
23.47%
+756.88K
2024Q2
27
1.82M
24.31%
-214.81K
2024Q1
20
1.77M
23.82%
-386.75K
2023Q4
19
1.75M
24.04%
-404.23K
2023Q3
19
1.79M
24.48%
+126.81K
2023Q2
18
1.72M
23.56%
+25.67K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Elson (Marilyn)
1.54M
8.7%
--
--
Jun 04, 2025
Hu (Benjamin)
377.10K
2.14%
+36.46K
+10.70%
Sep 29, 2025
White (Mark)
309.13K
1.75%
--
--
Jun 04, 2025
Owens (David)
185.75K
1.05%
+36.46K
+24.42%
Sep 29, 2025
The Vanguard Group, Inc.
159.88K
0.91%
--
--
Jun 30, 2025
MYDA Advisors LLC
800.00K
4.53%
+800.00K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
116.37K
0.66%
+2.30K
+2.01%
Jun 30, 2025
Kazden (Alan)
83.13K
0.47%
--
--
Jun 04, 2025
Renaissance Technologies LLC
46.34K
0.26%
+46.34K
--
Jun 30, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Nexalin Technology Inc的前五大股东是谁?

Nexalin Technology Inc 的前五大股东如下:
Elson (Marilyn)持有股份:1.54M,占总股份比例:8.70%。
Hu (Benjamin)持有股份:377.10K,占总股份比例:2.14%。
White (Mark)持有股份:309.13K,占总股份比例:1.75%。
Owens (David)持有股份:185.75K,占总股份比例:1.05%。
The Vanguard Group, Inc.持有股份:159.88K,占总股份比例:0.91%。

Nexalin Technology Inc的前三大股东类型是什么?

Nexalin Technology Inc 的前三大股东类型分别是:
Elson (Marilyn)
Hu (Benjamin)
White (Mark)

有多少机构持有Nexalin Technology Inc(NXL)的股份?

截至2025Q3,共有37家机构持有Nexalin Technology Inc的股份,合计持有的股份价值约为1.33M,占公司总股份的7.29%。与2025Q2相比,机构持股有所增加,增幅为-9.24%。

哪个业务部门对Nexalin Technology Inc的收入贡献最大?

在FY2025Q2,Equipment 业务部门对Nexalin Technology Inc的收入贡献最大,创收52.53K,占总收入的74.41%。
KeyAI